Severe Symptomatic Aortic Stenosis (Defined as New York Heart Association (NYHA) Class ≥ II)

1

Review clinical trials related to Severe Symptomatic Aortic Stenosis (Defined as New York Heart Association (NYHA) Class ≥ II). Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

PERFECT - Portuguese Evolut Registry Studying the Outcomes of Medtronic Evolut™ FX+ TAVI System by Evaluating an Optimal Care Pathway for TAVI

The goal of this registry is to learn how the Medtronic Evolut™ FX+ transcatheter aortic valve implantation (TAVI) System performs in adults with severe, symptomatic aortic stenosis who need valve replacement. The main questions it aims to answer are: * Can using a standardized procedure for the impantation of the Medtronic Evolut™ FX+ TAVI System increase safety and efficiency? * What are the short-term (30 days) and long-term (1 year) patient outcomes, including the need for a pacemaker, complications, and valve function? Participants will undergo TAVI with the Medtronic Evolut™ FX+ TAVI System as part of their routine care. Be followed during their hospital stay, at 30 days, and at 1 year to check heart health, valve function, and recovery. 500 people at 12 hospitals in Portugal will take part in this registry.

Participants needed: 500
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Portuguese Association of Interventional CardiologyUpdated: Jul 2, 2026Locations: 12Duration: 1 Year
Eligibility criteria

Severe symptomatic (defined as New York Heart Association (NYHA) class ≥ II) aor... [+1]

Subjects with pre-existing surgical bioprosthetic aortic valve; [+5]